Thursday, November 5, 2026

Back to the front page

From X

@david_katunaric 1 click

Mikro Kap David on X

Q3 absolutely sucked, and my performance currently stands at 37.8% YTD versus 65.8% at the end of Q2, marking the worst drawdown from a high since I started sharing my buy/sell decisions on Substack. Apparently, the Market Gods decided this is what you get for calling your last portfolio update “Half-time Lead.” …I’m just glad I didn’t use a Buffett quote. That might’ve finished me off. While I barely felt the pre-2024 election volatility, the spring 2025 tariff scare, or the start of the Iran war in 2026, Q3 broke that pattern. $EVC, my largest position, fell more than 40% from its highs and made sure I felt this one. The portfolio’s relative resilience, something I’d come to appreciate, disappeared with it. Of course, I have plenty to say about Entravision, but I’ll save the fundamental developments for later in the article. Q3 was a season of portfolio pruning (wow, I never thought I’d use that phrase). I exited two winners, realized one loss, added to a large position, saw a rare billion-dollar-plus company find its way into my portfolio, and ended the quarter with 6% in cash versus 0% at the end of Q2. I ended Q3 with 11 holdings, with the top three accounting for 53% of capital and the top five for 70%. Portfolio beta also came down from 0.95 at the end of Q2 to 0.80 at quarter end. That is still elevated relative to the portfolio’s historical level, largely because my biggest position carries a beta of 1.68, while every other holding sits below 1. I’ll save the longer performance review for year end, when we can hopefully put what I still consider a satisfactory 2026 into proper perspective. For now, I think it’s better to focus on what actually matters for a concentrated stock picker like me: what has changed fundamentally, how those developments affect the risk/reward, and where my conviction stands today. As usual, at the link below I went through the portfolio from the smallest position to the largest.

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

Thursday Tailwinds #13: Nov 5, 2026

Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…

eToro: Expanding Beyond Crypto

EToro trades at 2.89x EV/FCF with $304 million in trailing free cash flow, expanding from crypto into equities, commodities, currencies and…

CHWY · long

Chewy INC

Chewy (CHWY) is presented as a long opportunity after a prior 2022 short thesis played out.

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

Coupang: 3Q26 Business Recap

Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.